Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Hepatology


Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes

February 16th 2022

Empagliflozin may reduce steatosis but not fibrosis risk in individuals with type 2 diabetes and cardiovascular disease. The improvements in cardiorenal outcomes and mortality associated with empagliflozin therapy appear to be independent of steatosis and fibrosis risk (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Hepatology, Medication, Nephropathy, News
Tags: Empagliflozin, fibrosis, steatosis

Categories: Cardiovascular, Hepatology, Medication, Nephropathy
Tags: Empagliflozin, fibrosis, steatosis

An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care

February 1st 2022

From the perspectives of health practitioners, there is a gap in clinical practice for the implementation of clear, evidence-based guidelines for NAFLD in people with T2D. By focusing on comorbidity prevention and integrating NAFLD as a diabetes complication to be addressed during established cycles of care, many barriers to implementing a NAFLD pathway in primary care could be overcome (Diabetic Medicine)

Categories: Hepatology, Management, News
Tags: NAFLD, Type 2 Diabetes

Categories: Hepatology, Management
Tags: NAFLD, Type 2 Diabetes

The Association Between Vitamin D and Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease: An Observational Cross-Sectional Study

February 1st 2022

This study suggests that T2DM people with BMI > 23kg/m2 were more susceptible to NAFLD by vitamin D deficiency and that it is necessary to maintain optimal serum vitamin D levels in this population (Metabolic Syndrome and Obesity)

Categories: Hepatology, News
Tags: NAFLD, Type 2 Diabetes, Vitamin D

Categories: Hepatology
Tags: NAFLD, Type 2 Diabetes, Vitamin D

Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database

January 5th 2022

Elevated liver enzymes are common in patients with T2D and clearly correlate with a higher prevalence of clinically relevant comorbidities. Assessing liver enzymes should be standard clinical routine in T2D due to a possible predictive role for comorbidities and complications (Diabetes, Obesity and Metabolism)

Categories: Hepatology, News, Pathology
Tags: comorbidities, liver enzymes, Type 2 Diabetes

Categories: Hepatology, Pathology
Tags: comorbidities, liver enzymes, Type 2 Diabetes

Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials

September 7th 2021

Treatment with SGLT2 inhibitors improves liver structure and function in patients with T2D. This meta-analysis suggests that SGLT2 inhibitors are a promising pharmacological approach for treatment of NAFLD (Diabetes/Metabolism Research and Reviews)

Categories: Hepatology, Medication, News
Tags: NAFLD, SGLT2 inhibitors

Categories: Hepatology, Medication
Tags: NAFLD, SGLT2 inhibitors

Impact of SGLT2 inhibitors in comparison to DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin

July 7th 2021

In comparison to DPP4i, SGLT2i may improve survival for patients with cirrhosis who require additional pharmacotherapy for DM beyond metformin, but confirmatory studies are necessary (Diabetes, Obesity and Metabolism)

Categories: Hepatology, News
Tags: Cirrhosis, DPP4 inhibitors, SGLT2 inhibitors

Categories: Hepatology
Tags: Cirrhosis, DPP4 inhibitors, SGLT2 inhibitors

The association of laminin levels with insulin resistance and non-alcoholic hepatosteatosis

June 7th 2021

Our study results suggest that, although there is no exact link between laminin and non-alcoholic hepatosteatosis, serum laminin levels are lower in patients with insulin resistance by regulating the insulin effect through integrins (Diabetes and Metabolic Syndrome)

Categories: Hepatology, News
Tags: laminin, non-alcoholic hepatosteatosis

Categories: Hepatology
Tags: laminin, non-alcoholic hepatosteatosis

Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes

March 14th 2021

Given the absence of approved therapies for NAFLD-fibrosis, it would be reasonable to initiate specific randomized controlled trials with statins (Metabolism – Clinical and Experimental)

Categories: Hepatology, News
Tags: statin, Type 2 Diabetes

Categories: Hepatology
Tags: statin, Type 2 Diabetes

Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial

December 12th 2017

Statin therapy is safe in patients with prediabetes/T2DM and NASH. Given their high cardiovascular risk, statin therapy should be encouraged in this population (JCEM)

Categories: Hepatology, News
Tags: NASH, statin, Type 2 Diabetes

Categories: Hepatology
Tags: NASH, statin, Type 2 Diabetes

Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study

April 20th 2016

Our findings demonstrate that prediabetic patients show a lower phenotypic flexibility after external aggression, such as OFTT compared with nondiabetic patients. The postprandial response increases progressively according to non-diabetic, prediabetic and type 2 diabetic state and it is higher in patients with liver insulin-resistance. To identify this subgroup of patients is important to treat more intensively in order to avoid future cardiometabolic complications (Cardiovascular Diabetology)

Categories: Hepatology, News
Tags: Insulin resistance, lipoprotein

Categories: Hepatology
Tags: Insulin resistance, lipoprotein

The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes

March 30th 2016

Fatty Liver Index assessed nonalcoholic fatty liver disease (FLI-NAFLD) was present in the majority of T2DM patients of our sample and metabolic derangement, not alcohol consumption, was mainly associated with the disease. FLI-NAFLD patients have a worse metabolic profile (Journal of Diabetes Research)

Categories: Hepatology, News
Tags: NAFLD, Type 2 Diabetes

Categories: Hepatology
Tags: NAFLD, Type 2 Diabetes

Assessment of the relation between non-alcoholic fatty liver disease and diabetic complications

March 19th 2016

NAFLD combined with type 2 diabetes is associated with the presence of significant coronary artery disease and hypertension (Journal of Diabetes Investigation)

Categories: Hepatology, News
Tags: NAFLD

Categories: Hepatology
Tags: NAFLD

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

November 20th 2015

Liraglutide was safe, well tolerated, and led to histological resolution of non-alcoholic steatohepatitis, warranting extensive, longer-term studies (The Lancet)

Categories: Hepatology, News
Tags: liraglutide, NAFLD

Categories: Hepatology
Tags: liraglutide, NAFLD

Effect of T2D on risk of hepatocellular carcinoma in chronic Hep C

October 11th 2012

T2DM causes an approximately 1.7-fold enhancement in the development of HCC and malignancies other than HCC in HCV-positive patients treated with IFN (Hepatology)

Categories: Hepatology, News

Categories: Hepatology

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Napp DiabetesNovo NordiskBoehringer IngelheimAstraZeneca

Silver Sponsors

Abbott Diabetes CareAbout Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership